BioVectra - News & Press Releases



	August 29, 2011 Dale Zajicek appointed President of BioVectra Inc.... read more April 19, 2011 Doe & Ingalls and BioVectra Expand Partnership To Better Serve Biotech Companies... read more January 14, 2011 BioVectra Expansion of cGMP Contract Fermentation Capacity Nears Completion... read more


Home • News & Press Releases
News & Press Releases

	2011-08-29 - Dale Zajicek appointed President of BioVectra Inc. Ron Keefe, CEO of BioVectra Inc., is pleased to announce the appointment of Dale Zajicek as President of the company. 2011-04-19 - Doe & Ingalls and BioVectra Expand Partnership To Better Serve Biotech Companies Doe & Ingalls, a leading chemical services provider, and BioVectra, a specialized cGMP manufacturer of API’s and bioprocessing materials, jointly announced today the renewal and expansion of their partnership agreement. The new 3-year agreement names Doe & Ingalls the exclusive distribution partner for BioVectra bioprocessing reagents in the United States and Puerto Rico. 2011-01-14 - BioVectra Expansion of cGMP Contract Fermentation Capacity Nears Completion In response to increasing client demand, BioVectra Inc. says it is completing final qualification on a capacity expansion of its cGMP microbial contract fermentation services at its facility in Charlottetown, Prince Edward Island, Canada. The new manufacturing suite will be available for clinical production of fermentation API’s in March, 2011. 2010-10-19 - BioVectra Inc. founder recognized by Ernst & Young’s Entrepreneur of the Year program Today, Dr. Regis Duffy was named the Ernst & Young Entrepreneur Of The Year® 2010 Atlantic Lifetime Achievement Award recipient in recognition of his commitment to the PEI business community and his substantial entrepreneurial achievements. Dr. Duffy is Entrepreneur Of The Year’s ninth award recipient from Atlantic Canada. 2010-10-06 - Dr. Regis Duffy honoured as recipient of the Order of Prince Edward Island The honour is awarded as a means of recognizing those Islanders who have shown individual excellence or outstanding leadership in their community and in their chosen occupation or profession. It is the highest honour that can be accorded to a citizen of the Province. It is awarded annually following a public nomination process with not more than three recipients being selected by an independent nine-person Advisory Council each year. Insignia of the Order will be presented by Her Honour the Lieutenant Governor at a special investiture ceremony on October 6th at Government House, Charlottetown. 2010-09-07 - Major Investment in Expanded Custom Synthesis and Fermentation Facilities in BioVectra’s Canadian headquarters are currently undergoing expansion for both custom synthesis and fermentation. In response to its consistent performance as a manufacturing partner to major pharma and biotech, client demand continues to grow steadily as products progress through clinical development. BioVectra is investing over $18.5M USD in two separate expansion projects, furthering its commitment to contract manufacturing. 2010-08-19 - BioVectra gets $14.8M provincial loan BioVectra Inc. president Ron Keefe said the loan will be used to expand the company's facility near the Charlottetown airport to make a pharmaceutical product for an international company. 2010-05-12 - Ron Keefe recognized as one of Atlantic Canada's Top 50 CEO’s for 2010 BioVectra's President and CEO, Ron Keefe, has been recognized by Atlantic Business Magazine as one of Atlantic Canada's Top 50 CEO’s for 2010. The magazine has been publishing its Top 50 list since 1999 and it honours Atlantic Canada’s top business leaders. Winners were announced May 12th at an Awards Gala held at the World Trade & Convention Centre in Halifax, Nova Scotia. 2010-04-28 - BioVectra announces expansion of its cGMP contract fermentation capacity BioVectra Inc. announced today it is investing in a capacity expansion of its cGMP microbial contract fermentation services at its facility in Charlottetown, Prince Edward Island, Canada. 2010-01-04 - BioVectra confirms partnership to market Docetaxel in the U.S.A. BioVectra Inc. announced today it has signed agreements with Sandoz Inc. of Princeton, New Jersey, for Sandoz to commercialize and market the Abbreviated New Drug Application (ANDA) for Docetaxel for injection, the generic version of Taxotere®, developed by BioVectra. 2009-09-22 - BioVectra announces Oncolix Inc. signs manufacturing and investment agreement BioVectra, Inc., a cGMP manufacturing and development partner in Charlottetown, PE, Canada, announces that it has reached an agreement with Oncolix Inc., a biopharmaceutical company based in Houston, Texas, to manufacture ProlantaTM for human clinical testing. As part of this agreement, BioVectra will be investing $1.5 million in Oncolix. Prolanta is a targeted therapeutic protein under development for the treatment of breast and ovarian cancer. 2008-09-13 - Red Cross Honours Regis Duffy With Humanitarian Award Regis Duffy, a well-known entrepreneur and former dean of science and chair of the board of governors at UPEI, is the recipient of the Canadian Red Cross 2008 Humanitarian Award in Prince Edward Island. 2008-07-06 - BioVectra Announces Collaboration BioVectra DCL and the National Research Council Institute for Nutrisciences and Health (NRC-INH) today announced their collaborative research agreement aimed at identifying a platform of new drug candidates with unique neuroprotective properties. 2008-05-15 - BioVectra Inc. and Doe & Ingalls of Maryland Partner to Serve Biotech Companies Doe & Ingalls of Maryland, LLC has signed an exclusive agreement to distribute BioVectra Inc.’s bioprocessing reagents, molecular biology reagents and enzymes in the United States. 2008-04-28 - Bioscience and health research centre named after Regis and Joan Duffy The state-of-the-art bioscience and health research centre at the University of Prince Edward Island has been named the Regis and Joan Duffy Research Centre in honour of the well-known Island couple. 2008-04-08 - BioVectra Inc. and Taxolog Submit DMF for Docetaxel As part of their previously announced technology development partnership, BioVectra Inc. (Charlottetown, Prince Edward Island, Canada), and Taxolog, Inc (Fairfield, New Jersey, USA) announced today that they have achieved a key milestone in their docetaxel development and commercialization plan with the submission of the United States Drug Master File (DMF) for the manufacturing of the active pharmaceutical ingredient. 2008-01-28 - BioVectra Awarded $3MM to Support Partnering in Development of New Drug Compounds BioVectra Inc.announced today that it has received $3MM in funding secured to advance a program in support of new drug development, using strategic partnering to advance new candidates towards commercialization. 2008-01-17 - New Agreement Signed with Helix Helix BioPharma Corp. (TSX, FSE: “HBP”) has announced that it has signed an agreement with Charlottetown, P.E.I.-based BioVectra DCL, a division of Diagnostic Chemicals Limited, to manufacture L-DOS47 bulk drug product for human clinical testing. 2007-10-03 - BioVectra and Taxolog Partner for Docetaxel ANDA BioVectra dcl and Taxolog, Inc. have announced their partnership to commercialize proprietary technologies for taxane semi-synthesis and submission of an ANDA for formulated docetaxel. 2007-06-29 - BioVectra Announces New Agreement SyntheMed, Inc., a biomaterials company headquartered in Iselin, New Jersey, has announced that it has entered into a long-term supply agreement with BioVectra, for supply of raw material used in the production of its bioresorbable adhesion barrier film, REPEL-CV.